The BioNTech SE ADR BNTX rose 1.18% to $115.30 Thursday, on what proved to be an all-around rough trading session for the ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...

BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen ...

BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...